During the past decade, Cumberland Valley Retina Consultants conducted 44 clinical trials. In the 10-year time frame, 44 clinical trials started and 8 clinical trials were completed, i.e. on average, 18.2% percent of trials that started reached the finish line to date. In the past 5 years, 30 clinical trials started and 6 clinical trials were completed. i.e. 20% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Cumberland Valley Retina Consultants" #1 sponsor was "Clearside Biomedical, Inc." with 5 trials, followed by "Kodiak Sciences Inc" with 5 trials sponsored, "Hoffmann-La Roche" with 4 trials sponsored, "Apellis Pharmaceuticals, Inc." with 3 trials sponsored and "Genentech, Inc." with 3 trials sponsored. Other sponsors include 24 different institutions and companies that sponsored additional 30 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Cumberland Valley Retina Consultants" #1 collaborator was "Pfizer" with 3 trials as a collaborator, "AbbVie" with 1 trials as a collaborator, "Clinical Trials Resource Group, LLC" with 1 trials as a collaborator, "Eyetech Pharmaceuticals" with 1 trials as a collaborator and "Laboratorios Thea, France" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Cumberland Valley Retina Consultants" are "Diabetic Macular Edema" (8 trials), "Diabetic Retinopathy" (6 trials), "Geographic Atrophy" (5 trials), "Macular Degeneration" (5 trials) and "Neovascular Age-related Macular Degeneration" (4 trials). Many other conditions were trialed in "Cumberland Valley Retina Consultants" in a lesser frequency.

Most popular intervention types in "Cumberland Valley Retina Consultants" are "Drug" (43 trials), "Other" (14 trials), "Device" (3 trials), "Combination Product" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Sham Procedure" (10 trials), "Aflibercept" (6 trials), "KSI-301" (5 trials), "Placebo" (5 trials) and "Ranibizumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Cumberland Valley Retina Consultants" are 49 trials for "All" genders.

Currently, there are NaN active trials in "Cumberland Valley Retina Consultants". undefined are not yet recruiting, 12 are recruiting, 10 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 17 completed trials in Cumberland Valley Retina Consultants, undefined suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in Cumberland Valley Retina Consultants, 5 "Phase 1" clinical trials were conducted, 24 "Phase 2" clinical trials and 18 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 3 trials that are defined as “Not Applicable".